Bio Wellness 444 LLC
FDA issued a warning letter to Bio Wellness 444 LLC (Oldsmar, FL, United States) on May 30, 2025, citing 21 CFR 201.128 and 21 CFR 310.548. Subject: Unapproved New Drugs, Misbranded.
From the letter: “Based on the above labeling evidence “Silver Bullet elite douche” and “Silver D elite douche” are over-the-counter (OTC) colloidal silver-containing drug products intended for use in the treatment of vaginal infections.”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 2 findings · 2 issue types
- Cited
- 21 CFR 201.128, 21 CFR 310.548
- Response due
- 15 working days after receipt of this letter
- FDA asks for
- 4 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Labeling, claims & marketing · 21 CFR 201.128, 21 CFR 310.548(b)The products are labeled and promoted as OTC drugs for treating vaginal infections without FDA approval.
Based on the above labeling evidence “Silver Bullet elite douche” and “Silver D elite douche” are over-the-counter (OTC) colloidal silver-containing drug products intended for use in the treatment of vaginal infections.
02Registration, listing & premarketThe products are unapproved new drugs marketed without an approved application, violating the FD&C Act.
No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Thus, “Silver Bullet elite douche” and “Silver D elite douche” are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a).
What FDA requested
- Notify FDA in writing within 15 working days of corrective steps taken
- Provide explanation of each step to prevent recurrence of violations
- Submit copies of related documentation
- Include reasoning and supporting information if products are not in violation
FDA Warning Letter
24 paragraphs · 5 sectionsText as published on FDA.gov, retrieved Oct 16, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
1Introduction
2 paragraphs
This letter is to advise you that on March 10th, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website, biowellness444.com, where your “Silver Bullet elite douche” and “Silver D elite douche” drug products are available for purchase in the United States without a prescription. We also reviewed your social media on Instagram at “biowellness444,” which directs consumers to your website to purchase your products.
“Silver Bullet elite douche” and “Silver D elite douche” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a), 331(d). These violations are described in more detail below.
2Unapproved New Drug Violations
2 paragraphs
“Silver Bullet elite douche” and “Silver D elite douche” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.
Examples from the “Silver Bullet elite douche” and “Silver D elite douche” product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:
3“Silver Bullet elite douche”
1 paragraph
“Why Silver Bullet Elite Douche? Colloidal silver has been used for over 2,000 years to relieve the symptoms of various health condition including the effects of viruses and bacterial infections. Silver Bullet incorporates colloidal silver containing 0.8 nanometers with 99% bioactive silver ions… [from product label]
4“Silver Bullet elite douche” and “Silver D elite douche”
8 paragraphs
“…Biowellness 444 stands out-largely due to our proprietary blend of powerful, all-natural with only 2-ingredients: ·Colloidal Silver: Known for its potent antibacterial effects…” [from your product website]
“Check out my douche, the elite douche, it’s a formula of colloidal silver, which has been used for thousands of years to combat all strands of bacteria…so if you have any issues with bacterial vaginosis or yeast infections use my douche you’ll see immediate results…” [transcription from your Instagram social media page video]
“Hey ladies, if you have any issues down there such as bacterial vaginosis or yeast infections check out my product, the elite douche. That’s the three-day cleanser, the one-day cleanser and it will give you immediate relief…” [transcription from your Instagram social media page video]
“Frequently Asked Questions (FAQs)…What makes your product so different from the other products on the market? We are the only Douche Product on the market that contains the combination of Colloidal Silver and Tea Tree Oil...” [from your product website]
“Testimonials… ‘This product is amazing! I had the onset of a yeast infection and tried this product for instant relief. I’m very prone to UTI’s and yeast infections. I’ve never felt relief as quickly as I did after first use…” [from your product website]
“Tea tree oil and colloidal silver are better together…Combining these two, natural antibiotics has proven to be make them [sic] more effective at killing microorganisms...” [from your product website]
Based on the above labeling evidence “Silver Bullet elite douche” and “Silver D elite douche” are over-the-counter (OTC) colloidal silver-containing drug products intended for use in the treatment of vaginal infections. The Agency has determined that any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and/or prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the FD&C Act, and that all such products are deemed to be new drugs and require an approved new drug application or abbreviated new drug application under section 505 of the FD&C Act to be lawfully marketed according to 21 CFR 310.548(b).
No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Thus, “Silver Bullet elite douche” and “Silver D elite douche” are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of these products into interstate commerce violates section 301(d) of the FD&C Act, 21 U.S.C. 331(d).
5Conclusion
3 paragraphs
The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
Regulations
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Oldsmar, FL, United States
- Letter posted date
- Jun 10, 2025
- Letter issue date
- May 30, 2025
- Addressed to
- Bridget Conzemius, Co-Owner
- Inspection dates
- Not recorded
- Response window
- 15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations.
- Record length
- 979 words · 0 recorded redactions
- Published status
- No published close-out
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 11, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.